Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Somavaratan versus daily recombinant human growth hormone in prepubertal children with growth hormone deficiency
NL-OMON42218Phase 3Not yet recruiting
- Sponsor
- Versartis, Inc.
- Start
- Apr 2015
- Modality
- Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in growth hormone deficiency (GHD) comparing Somavaratan every 15 days with Daily recombinant human growth hormone (2 arms). Primary endpoints: Annual height velocity and Safety. Planned start Apr 2015; status: not yet recruiting.
02
Drugs
somavaratansomatropin
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on NL-OMON42218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42218.